Navigation Links
U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent
Date:7/29/2011

INDIANAPOLIS, July 29, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has overturned a prior ruling by the U.S. District Court for the District of New Jersey and has upheld the validity of the company's method-of-use patent on Strattera® (atomoxetine). In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled in favor of Lilly, upholding the method-of-use patent which provides protection for Strattera through May of 2017.

"We are pleased with today's ruling from the Court of Appeals regarding Strattera's method-of-use patent and remain confident that the patent is valid and enforceable," said Robert A. Armitage, senior vice president and general counsel for Lilly. "In overturning the prior district court ruling, we believe that the Court fairly applied long-standing patent law principles."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Strattera patent litigation. These statements are based on management's current expectations but actual results may differ materially.  There can be no assurance that the company will prevail in any appeal. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Strattera® (atomoxetine, Lilly)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
2. Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case
3. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
4. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
5. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
6. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
7. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
8. Court Certifies Overtime Class Action Against Forest Labs, According to The Ottinger Firm, P.C.
9. Lilly Comments on Court Ruling in Amylin Litigation
10. Federal Court Asked to Compel Decision in Marijuana Scheduling Action
11. 83 Cases of Autism Associated with Childhood Vaccine Injury Compensated in Federal Vaccine Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
Breaking Medicine News(10 mins):